Mangoceuticals, Inc.
MGRX· Nasdaq
MGRXMangoceuticals, Inc.
Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001493152-24-032410
| Metric | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|
| Revenue | $163.16K | $141.24K | — |
| Net Income | -$2.39M | -$2.28M | -$310.19K |
| EPS Diluted | -$1.37 | -$0.14 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end
